| 88 | 0 | 101 |
| 下载次数 | 被引频次 | 阅读次数 |
目的 分析2011—2025年脂质合成在代谢功能障碍相关脂肪性肝病（MASLD）中的研究现状及趋势。方法 检索Web of Science核心合集中2011年1月1日—2025年9月1日发表的脂质合成相关文献，采用VOSviewer 1.6.20和CiteSpace 6.3.R1软件进行计量学分析与可视化。结果 共纳入635篇英文文献，年发文量总体上升，2016年以来增长尤为显著。中国与美国学者发文量分居前两位；美国学者文献总被引及高影响力机构领先。发文量较高的期刊属于JCR Q1/Q2区，Nutrients为发文量最高期刊，Hepatology为最高被引期刊。核心作者HODSON L系统综述了脂质合成在代谢疾病中的作用；被引频次最高文献为DONNELLY K L的研究，该研究首次定量揭示了肝脏脂肪来源。共被引聚类分析显示，脂质合成调控、胰岛素抵抗（IR）的交互作用及饮食因素为当前研究重点。关键词分析显示，脂质合成与IR是核心热点。此外，果糖代谢、腺苷酸活化蛋白激酶（AMPK）调控及胆固醇代谢紊乱正成为新兴研究方向。结论 MASLD中脂质合成调控研究潜力显著，美国与中国为主要贡献国家，HODSON L与DONNELLY K L为核心影响作者。脂质调控与IR为当前研究热点，果糖代谢、AMPK信号及胆固醇代谢紊乱为新兴前沿。
Abstract：Objective To investigate research hotspots regarding lipogenesis mechanisms in hepatocytes in metabolic dysfunction-associated steatotic liver disease (MASLD) and their molecular regulation. Methods A search of the Web of Science Core Collection was conducted for literature related to lipogenesis published from January 1， 2011 to September 1， 2025. Bibliometric analysis and visualization were performed using VOSviewer 1.6.20 and CiteSpace 6.3.R1. Results A total of 635 English-language articles were included. The annual publication output showed an overall upward trend， with a particularly marked increase after 2016; the highest annual output was 7.4 times that of 2011. China and the United States ranked first and second in publication volume; the United States led in total citations (14，592) and in the number of high-impact institutions. Journals with high publication output all fell within the JCR Q1/Q2 categories， with Nutrients publishing the most articles and Hepatology receiving the highest citations. Core author Hodson L systematically reviewed the role of lipogenesis in metabolic diseases; the most highly cited article was the pioneering study by Donnelly K L， which was the first to quantitatively determine the sources of hepatic fat. Co-citation cluster analysis revealed that the regulation of lipogenesis， interaction with insulin resistance (IR)， and dietary factors were the current research focuses. Keyword analysis showed that lipogenesis and IR were the two central research hotspots in this field. In addition， fructose metabolism， AMP-activated protein kinases (AMPK) regulation， and disorders of cholesterol metabolism were gradually emerging as new research directions. Conclusion Research on the regulation of lipid synthesis in MASLD shows significant potential. The United States and China are the major contributing countries， and Hodson L and Donnelly KL are the core influential authors. Lipid regulation and IR are the current research hotspots， while fructose metabolism， AMPK signaling， and disorders of cholesterol metabolism are emerging frontiers. Bibliometric and visualization analysis can effectively sort out the research context， and help track frontiers and predict trends.
[1] RINELLA M E， LAZARUS J V， RATZIU V， et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature[J]. J Hepatol， 2023，79(6):1542-1556.
[2] Younossi Z M， Golabi P， Paik J M， et al. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review[J]. Hepatology， 2023，77(4):1335-1347.
[3] Marchisello S， Di Pino A， Scicali R， et al. Pathophysiological， molecular and therapeutic issues of nonalcoholic fatty liver disease: an overview[J]. Int J Mol Sci， 2019，20(8):1948.
[4] Loomba R， Friedman S L， Shulman G I. Mechanisms and disease consequences of nonalcoholic fatty liver disease[J]. Cell， 2021，184(10):2537-2564.
[5] Lambert J E， Ramos-Roman M A， Browning J D， et al. Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease[J]. Gastroenterology， 2014，146(3):726-735.
[6] Ramos-Molina B， Rossell J， PEREZ-MONTES DE OCA A， et al. Therapeutic implications for sphingolipid metabolism in metabolic dysfunction-associated steatohepatitis[J]. Front Endocrinol (Lausanne)， 2024，15:1400961.
[7] Esler W P， Cohen D E. Pharmacologic inhibition of lipogenesis for the treatment of NAFLD[J]， J Hepatol， 2024，80(2):362-377.
[8] Xia D， Yao R， Wang S， et al. Mapping trends and hotspots regarding clinical research on COVID-19: a bibliometric analysis of global research[J]. Front Public Health， 2021，9:713487.
[9] Bakkalbasi N， Bauer K， Glover J， et al. Three options for citation tracking: Google Scholar， Scopus and Web of Science[J]. Biomed Digit Libr， 2006，3:7.
[10] van Eck N J， Waltman L. Software survey: VOSviewer， a computer program for bibliometric mapping[J]. Scientometrics， 2010，84(2):523-538.
[11] Liao H， Tang M， Luo L， et al. A bibliometric analysis and visualization of medical big data research[J]. Sustainability， 2018，10(1):166.
[12] Synnestvedt M B， Chen C， Holmes J H. CiteSpace Ⅱ: visualization and knowledge discovery in bibliographic databases[J]. AMIA Annu Symp Proc， 2005，2005:724-728.
[13] Yang Q， Yang D， Li P， et al. A bibliometric and visual analysis of global community resilience research[J]. Int J Environ Res Public Health， 2021，18(20):10857.
[14] Yang S， Yu D， Liu J， et al. Global publication trends and research hotspots of the gut-liver axis in NAFLD: a bibliometric analysis[J]. Front Endocrinol (Lausanne)， 2023，14:1121540.
[15] Wang L， Jiang J， Li Y， et al. Global trends and hotspots in research on osteoporosis rehabilitation: A bibliometric study and visualization analysis[J]. Front Public Health， 2022，10:1022035.
[16] Lawitz E J， Coste A， Poordad F， et al. Acetyl-CoA carboxylase inhibitor GS-0976 for 12 weeks reduces hepatic de novo lipogenesis and steatosis in patients with nonalcoholic steatohepatitis[J]. Clin Gastroenterol Hepatol， 2018，16(12):1983-1991.
[17] Westcott F， Dearlove D J， Hodson L. Hepatic fatty acid and glucose handling in metabolic disease: Potential impact on cardiovascular disease risk[J]. Atherosclerosis， 2024，394:117237.
[18] Donnelly K L， Smith C I， Schwarzenberg S J， et al. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease[J]. J Clin Invest， 2005，115(5):1343-1351.
[19] Chen Y， Chen Y， Tan S， et al. Visual analysis of global research on immunotherapy for gastric cancer: A literature mining from 2012 to 2022[J]. Hum Vaccin Immunother， 2023，19(1):2186684.
[20] Dou Y， Guo X， Wang X， et al. The research progress and prospects of circadian rhythm in obesity: a bibliometric analysis[J]. Front Nutr， 2025，11:1499984.
[21] Bo T， Gao L， Yao Z， et al. Hepatic selective insulin resistance at the intersection of insulin signaling and metabolic dysfunction-associated steatotic liver disease[J]. Cell Metab， 2024，36(5):947-968.
[22] Smith G I， Shankaran M， Yoshino M， et al. Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease[J]. J Clin Invest， 2020，130(3):1453-1460.
[23] Carli F， Della Pepa G， Sabatini S， et al. Lipid metabolism in MASLD and MASH: from mechanism to the clinic[J]. JHEP Rep， 2024，6(12):101185.
[24] Sakurai Y， Kubota N， Yamauchi T， et al. Role of insulin resistance in MAFLD[J]. Int J Mol Sci， 2021，22(8):4156.
[25] Softic S， Cohen D E， Kahn C R. Role of dietary fructose and hepatic de novo lipogenesis in fatty liver disease[J]. Dig Dis Sci， 2016，61(5):1282-1293.
[26] Ter Horst K W， Serlie M J. Fructose consumption， lipogenesis， and non-alcoholic fatty liver disease[J]. Nutrients， 2017，9(9):981.
[27] Zhao P， Saltiel A R. From overnutrition to liver injury: AMP-activated protein kinase in nonalcoholic fatty liver diseases[J]. J Biol Chem， 2020，295(34):12279-12289.
[28] Woods A， Williams J R， Muckett P J， et al. Liver-specific activation of AMPK prevents steatosis on a high-fructose diet[J]. Cell Rep， 2017，18(13):3043-3051.
[29] Boudaba N， Marion A， Huet C， et al. AMPK re-activation suppresses hepatic steatosis but its downregulation does not promote fatty liver development[J]. EBioMedicine， 2018，28:194-209.
[30] Min H K， Kapoor A， Fuchs M， et al. Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease[J]. Cell Metab， 2012，15(5):665-674.
[31] Barbhuiya P A， Yoshitomi R， Pathak M P. Understanding the Link Between Sterol Regulatory Element Binding Protein (SREBPs) and Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD)[J]. Curr Obes Rep， 2025，14(1):36.
基本信息:
中图分类号:R575.5;G353.1
引用信息:
[1]陈茜,苏本玉,徐峰,等.2011—2025年脂质合成在代谢功能障碍相关脂肪性肝病中的研究现状及趋势[J].山东医药().
基金信息:
国家自然科学基金联合基金项目（区域创新发展联合基金）（U23A20469）; 国家自然科学基金项目（82401003，82130025）; 山东省自然科学基金项目（ZR2024QH174）; 山东第一医科大学（山东省医学科学院）临床-基础联合创新团队项目（202402）
2026-08-31
2026-08-31
2026-08-31